PMID- 12681023
OWN - NLM
STAT- MEDLINE
DCOM- 20030606
LR  - 20221207
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 5
IP  - 3
DP  - 2003 May
TI  - Addition of rosiglitazone to metformin is most effective in obese, 
      insulin-resistant patients with type 2 diabetes.
PG  - 163-70
AB  - AIM: These analyses were undertaken to evaluate the efficacy of the insulin 
      sensitizer rosiglitazone (RSG) when added to the therapy of obese type 2 diabetes 
      mellitus patients (T2DM) taking near-maximal doses (2.5 g/day) of metformin 
      (MET). In obese, insulin-resistant patients with T2DM who are inadequately 
      controlled on MET, the addition of an agent that reduces insulin resistance may 
      be a more rational and innovative approach than the addition of an insulin 
      secretagogue. METHODS: Data were pooled from two double-blind studies of RSG 
      added to 2.5 g/day MET, involving a total of 550 T2DM patients. Patients were 
      categorized as non-overweight, overweight and obese according to their baseline 
      BMI using WHO criteria (<25 kgm(-2), 25-30 kgm(-2), >30 kgm(-2) respectively). 
      RESULTS: RSG improved glycaemia (HbA1c) and fasting plasma glucose (FPG) to a 
      clinically significant extent in all three subgroups but the effect was most 
      pronounced in the obese patients. Improvements in HOMA estimates of insulin 
      resistance and beta-cell function were also greatest in the obese patients (4 mg: 
      -16% and +19%; 8 mg: -37% and + 33% respectively), as were reductions in fasting 
      insulin. The profile of adverse events was not demonstrably different in obese 
      patients from the non-obese. CONCLUSIONS: In obese type 2 diabetic patients 
      inadequately controlled on MET alone, addition of rosiglitazone improves 
      glycaemic control, insulin sensitivity and beta-cell function to a clinically 
      important extent.
FAU - Jones, T A
AU  - Jones TA
AD  - GlaxoSmithKline, Harlow, UK.
FAU - Sautter, M
AU  - Sautter M
FAU - Van Gaal, L F
AU  - Van Gaal LF
FAU - Jones, N P
AU  - Jones NP
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazoles)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus/blood/*drug therapy/physiopathology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Resistance
MH  - Islets of Langerhans/physiopathology
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - *Obesity
MH  - Randomized Controlled Trials as Topic
MH  - Rosiglitazone
MH  - Thiazoles/*therapeutic use
MH  - *Thiazolidinediones
EDAT- 2003/04/12 05:00
MHDA- 2003/06/07 05:00
CRDT- 2003/04/12 05:00
PHST- 2003/04/12 05:00 [pubmed]
PHST- 2003/06/07 05:00 [medline]
PHST- 2003/04/12 05:00 [entrez]
AID - 258 [pii]
AID - 10.1046/j.1463-1326.2003.00258.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2003 May;5(3):163-70. doi: 10.1046/j.1463-1326.2003.00258.x.